Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19

Author(s): Mark Laws, Yasmin M. Surani, Md. Mahbub Hasan, Yiyuan Chen, Peiqin Jin, Taha Al-Adhami, Madiha Chowdhury, Aqeel Imran, Ioannis Psaltis, Shirin Jamshidi, Kazi S. Nahar and Khondaker Miraz Rahman*

Volume 28 , Issue 19 , 2021

Published on: 21 July, 2020

Page: [3803 - 3824] Pages: 22

DOI: 10.2174/0929867327666200721161840

Price: $65

Abstract

The novel coronavirus (SARS-CoV-2) pandemic has created a global public health emergency. The pandemic is causing substantial morbidity, mortality and significant economic loss. Currently, no approved treatments for COVID-19 are available, and it is likely to takes at least 12-18 months to develop a new vaccine. Therefore, there is an urgent need to find new therapeutics that can be progressed to clinical development as soon as possible. Repurposing regulatory agency-approved drugs and experimental drugs with known safety profiles can provide important repositories of compounds that can be fast-tracked to clinical development. Globally, over 500 clinical trials involving repurposed drugs have been registered, and over 150 have been initiated, including some backed by the World Health Organisation (WHO). This review is intended as a guide to research into small-molecule therapies to treat COVID-19; it discusses the SARS-CoV-2 infection cycle and identifies promising viral therapeutic targets, reports on a number of promising pre-approved small-molecule drugs with reference to over 150 clinical trials worldwide, and offers a perspective on the future of the field.

Keywords: COVID-19, SARS-CoV-2, coronavirus, drug discovery, small-molecule therapeutics, clinical trials.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy